Cogent Biosciences, Inc.
Income Statement
| Line Item | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | Sep 2019 | Jun 2019 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $312.0K | $528.0K | $7.0M | $15.3M | $1.0M | $3.1M | $3.1M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $6.1M | $5.0M | $5.1M | $9.5M | $10.4M | $10.3M | $10.6M | $12.4M |
| SG&A Expense | $5.3M | $5.6M | $2.8M | $3.7M | $2.7M | $2.7M | $3.1M | $2.5M |
| Operating Income | $-11.5M | $-57.2M | $-7.4M | $-6.1M | $2.2M | $-12.0M | $-10.5M | $-11.8M |
| Operating Margin | — | -18,333.0% | -1,402.1% | -87.3% | 14.7% | -1,180.0% | -335.9% | -387.8% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-11.3M | $-50.0M | $-7.4M | $-6.1M | $2.3M | $-11.9M | $-10.5M | $-11.7M |
| Net Margin | — | -16,020.2% | -1,400.2% | -86.7% | 15.0% | -1,168.9% | -335.1% | -382.9% |
| EPS (Basic) | $-9.34 | $-5.07 | $-0.95 | $-0.81 | $0.07 | $-0.39 | $-0.34 | $-0.39 |
| EPS (Diluted) | $-9.34 | $-5.07 | $-0.95 | $-0.81 | $0.07 | $-0.39 | $-0.34 | $-0.39 |
| Shares Outstanding (Basic) | 32.3M | 10.7M | 31.2M | 30.8M | 30.66B | 30.66B | 30.51B | 30.08B |
| Shares Outstanding (Diluted) | 32.3M | 10.7M | 31.2M | 30.8M | 31.20B | 30.66B | 30.51B | 30.08B |
| Dividends Per Share | — | — | — | — | — | — | — | — |